Teriparatide side effects: what 112,086 FDA adverse event reports show

Teriparatide · 1,222 reaction terms · 371,590 drug–reaction co-reports · data 2026-09-14

Drug class

Parathyroid Hormone Analog

FDA label (Established Pharmacologic Class)

Who reports

112,086 reports · 37% serious · 5,304 with death outcome · 91% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Teriparatide Injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy.

FDA label, Indications and Usage

What it is

Teriparatide Injection is a recombinant human parathyroid hormone analog (PTH 1-34). It has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 7Likely indication confounding 10Reporting / coding artifact 1Lab value / disease marker 6Not in label — unassessed 15

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,182 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Injection site stinging	104	134.5 104.4–173.2ROR 134.6 · calibrated p 2e-8 ✓	77.0 EB05 65.3 · IC025 +5.5 3/3 methods agree	Labeled (related wording) related wording	–	not reported in cached trials
Muscle cramp	552	82.7 74.8–91.5ROR 83.1 · calibrated p 5e-7 ✓	57.2 EB05 53.3 · IC025 +5.6 3/3 methods agree	Labeled (related wording) related wording	serious n=79	not reported in cached trials
Urine calcium increased	87	71.3 55.7–91.3ROR 71.4 · calibrated p 2e-6 ✓	51.1 EB05 42.7 · IC025 +5.0 3/3 methods agree	Lab value / disease marker	84% consumer	not reported in cached trials
Growing pains	72	69.6 53.1–91.3ROR 69.6 · calibrated p 2e-6 ✓	50.1 EB05 41.1 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	100% consumer	not reported in cached trials
Vertebroplasty	108	59.7 48.1–74.2ROR 59.8 · calibrated p 5e-6 ✓	45.0 EB05 38.3 · IC025 +4.9 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=91	not reported in cached trials
Blood calcium increased	2,041	56.6 53.9–59.4ROR 57.6 · calibrated p 5e-6 ✓	43.5 EB05 41.9 · IC025 +5.4 3/3 methods agree	Lab value / disease marker	serious n=626 · 80% consumer	not reported in cached trials
Chest wall pain	73	51.0 39.3–66.0ROR 51.0 · calibrated p 2e-5 ✓	39.7 EB05 32.6 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=20 · 100% clinician	not reported in cached trials
Injection site burning	147	42.6 35.6–51.0ROR 42.7 · calibrated p 4e-5 ✓	34.7 EB05 30.2 · IC025 +4.7 3/3 methods agree	Labeled (related wording) related wording	100% clinician	not reported in cached trials
Injection site streaking	45	40.5 29.3–55.9ROR 40.5 · calibrated p 7e-5 ✓	32.9 EB05 25.6 · IC025 +4.1 3/3 methods agree	Labeled (related wording) related wording	100% consumer	not reported in cached trials
Osteitis deformans	50	34.4 25.4–46.5ROR 34.4 · calibrated p 2e-4 ✓	28.8 EB05 22.7 · IC025 +4.0 3/3 methods agree	Not in label — unassessed	serious n=32	not reported in cached trials
Buttock pain	35	31.8 22.2–45.5ROR 31.8 · calibrated p 3e-4 ✓	26.9 EB05 20.2 · IC025 +3.8 3/3 methods agree	Not in label — unassessed	–	not reported in cached trials
Pain exacerbated	35	31.8 22.2–45.5ROR 31.8 · calibrated p 3e-4 ✓	26.9 EB05 20.2 · IC025 +3.8 3/3 methods agree	Not in label — unassessed	–	not reported in cached trials
Vitamin d increased	74	25.5 20.0–32.5ROR 25.5 · calibrated p 7e-4 ✓	22.4 EB05 18.4 · IC025 +3.9 3/3 methods agree	Lab value / disease marker	serious n=20 · 100% consumer	not reported in cached trials
Bone fissure	46	23.1 17.0–31.4ROR 23.1 · calibrated p 0.001 ✓	20.5 EB05 16.0 · IC025 +3.6 3/3 methods agree	Not in label — unassessed	serious n=43	not reported in cached trials
Medial tibial stress syndrome	37	22.3 15.9–31.4ROR 22.4 · calibrated p 0.002 ✓	19.8 EB05 15.0 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	100% consumer	not reported in cached trials
Vitamin d abnormal	39	19.9 14.3–27.7ROR 19.9 · calibrated p 0.003 ✓	17.9 EB05 13.6 · IC025 +3.4 3/3 methods agree	Lab value / disease marker	100% consumer	not reported in cached trials
Blood parathyroid hormone decreased	130	17.8 14.9–21.3ROR 17.8 · calibrated p 0.004 ✓	16.3 EB05 14.0 · IC025 +3.7 3/3 methods agree	Likely indication confounding term in indications	serious n=33 · 80% consumer	not reported in cached trials
Fear of falling	70	17.8 13.9–22.7ROR 17.8 · calibrated p 0.004 ✓	16.2 EB05 13.2 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	serious n=19 · 100% consumer	not reported in cached trials
Compression fracture	450	17.6 16.0–19.4ROR 17.7 · calibrated p 0.004 ✓	16.2 EB05 14.9 · IC025 +3.8 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=337 · 75% consumer	NCT01343004: 2/818 (0.2%) on Teriparatide (serious AE)
Device operational issue	364	17.6 15.8–19.6ROR 17.6 · calibrated p 0.004 ✓	16.1 EB05 14.8 · IC025 +3.8 3/3 methods agree	Reporting / coding artifact	81% consumer	not reported in cached trials
Vitamin d decreased	671	15.8 14.6–17.1ROR 15.9 · calibrated p 0.005 ✓	14.6 EB05 13.7 · IC025 +3.7 3/3 methods agree	Lab value / disease marker	serious n=144 · 89% consumer	not reported in cached trials
Lower extremity mass	47	15.1 11.2–20.3ROR 15.1 · calibrated p 0.008 ✓	13.8 EB05 10.7 · IC025 +3.1 3/3 methods agree	Not in label — unassessed	100% consumer	not reported in cached trials
Difficulty in walking	261	15.1 13.3–17.1ROR 15.1 · calibrated p 0.007 ✓	14.0 EB05 12.6 · IC025 +3.6 3/3 methods agree	Not in label — unassessed	serious n=82	not reported in cached trials
Pelvic fracture	573	14.8 13.6–16.1ROR 14.9 · calibrated p 0.007 ✓	13.8 EB05 12.9 · IC025 +3.6 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious PRR 21.3	NCT01343004: 1/820 (0.1%) control (serious AE)
Pubis fracture	53	14.7 11.1–19.5ROR 14.7 · calibrated p 0.009 ✓	13.5 EB05 10.6 · IC025 +3.2 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=53	not reported in cached trials
Accidental needle stick	60	14.3 11.0–18.7ROR 14.4 · calibrated p 0.009 ✓	13.2 EB05 10.5 · IC025 +3.2 3/3 methods agree	Not in label — unassessed	–	not reported in cached trials
Hypercalciuria	35	14.2 10.1–20.1ROR 14.2 · calibrated p 0.011 ✓	12.9 EB05 9.5 · IC025 +2.9 3/3 methods agree	Labeled adverse reaction exact term	serious n=20	NCT01343004: 102/818 (12.5%) on Teriparatide; 74/820 (9.0%) control
Vascular injury	101	14.1 11.5–17.3ROR 14.1 · calibrated p 0.010 ✓	13.1 EB05 11.1 · IC025 +3.3 3/3 methods agree	Not in label — unassessed	100% consumer	not reported in cached trials
Bone pain	4,131	14.1 13.7–14.6ROR 14.6 · calibrated p 0.008 ✓	13.2 EB05 12.8 · IC025 +3.7 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 12.6 · serious PRR 7.6 · 84% consumer	not reported in cached trials
Blood calcium abnormal	115	13.9 11.5–16.8ROR 13.9 · calibrated p 0.010 ✓	12.9 EB05 11.0 · IC025 +3.3 3/3 methods agree	Lab value / disease marker	serious n=41 · 76% consumer	not reported in cached trials
Pharmaceutical product complaint	1,739	13.2 12.5–13.8ROR 13.4 · calibrated p 0.011 ✓	12.3 EB05 11.9 · IC025 +3.5 3/3 methods agree	Not in label — unassessed	age-adj. PRR 23.3 · serious PRR 30.0	not reported in cached trials
Spinal fracture	1,289	12.9 12.2–13.6ROR 13.0 · calibrated p 0.012 ✓	12.1 EB05 11.5 · IC025 +3.5 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious PRR 14.8 · 73% consumer	NCT01343004: 2/818 (0.2%) on Teriparatide (serious AE)
Fractured sacrum	79	12.7 10.1–16.0ROR 12.7 · calibrated p 0.015 ✓	11.8 EB05 9.7 · IC025 +3.1 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=68	not reported in cached trials
Thoracic vertebral fracture	181	12.2 10.5–14.2ROR 12.2 · calibrated p 0.016 ✓	11.4 EB05 10.1 · IC025 +3.2 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=144	NCT01709110: 2/683 (0.3%) on Teriparatide (serious AE)
Wrist fracture	729	12.1 11.2–13.0ROR 12.1 · calibrated p 0.016 ✓	11.4 EB05 10.7 · IC025 +3.4 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious PRR 13.1 · 72% consumer	NCT01343004: 2/818 (0.2%) on Teriparatide (serious AE)
Injection site bruising	4,780	12.0 11.7–12.4ROR 12.5 · calibrated p 0.014 ✓	11.3 EB05 11.1 · IC025 +3.5 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 12.2 · serious PRR 10.7 · 94% consumer	not reported in cached trials
Lumbar vertebral fracture	270	11.8 10.4–13.3ROR 11.8 · calibrated p 0.018 ✓	11.1 EB05 10.0 · IC025 +3.2 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=233	NCT01343004: 1/818 (0.1%) on Teriparatide (serious AE)
Waist circumference increased	61	11.5 8.9–15.0ROR 11.6 · calibrated p 0.021 ✓	10.6 EB05 8.5 · IC025 +2.9 3/3 methods agree	Not in label — unassessed	100% consumer	not reported in cached trials
Body height decreased	628	11.5 10.6–12.4ROR 11.5 · calibrated p 0.020 ✓	10.8 EB05 10.1 · IC025 +3.3 3/3 methods agree	Not in label — unassessed	serious n=196 · 88% consumer	not reported in cached trials
Injection site haemorrhage	4,507	11.2 10.9–11.6ROR 11.6 · calibrated p 0.019 ✓	10.6 EB05 10.4 · IC025 +3.4 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 13.5 · serious PRR 12.7 · 89% consumer	NCT01343004: 1/818 (0.1%) on Teriparatide (serious AE)

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

Concept	Reports	PRR 95% CI	Reading
Fall / fracture	9,776	4.94.8–5.0	signal
Tendon disorder	230	1.11.0–1.3	no difference
Serious infection	4,179	1.01.0–1.0	no difference
Stroke	1,304	1.00.9–1.0	no difference
Arrhythmia / qt	1,005	1.00.9–1.0	no difference
Depression	1,367	0.90.9–1.0	lower than other drugs
Osteonecrosis	271	0.90.8–1.0	lower than other drugs
Heart failure	797	0.80.8–0.9	lower than other drugs
Hyponatraemia	356	0.80.7–0.9	lower than other drugs
Opportunistic infection	596	0.80.8–0.9	lower than other drugs
Myocardial infarction	798	0.70.7–0.8	lower than other drugs
Anaemia	1,153	0.70.7–0.8	lower than other drugs
Venous thromboembolism	811	0.70.7–0.7	lower than other drugs
Malignancy	1,262	0.60.6–0.7	lower than other drugs
Pancreatitis	250	0.60.5–0.7	lower than other drugs
Hypoglycaemia	284	0.60.5–0.6	lower than other drugs

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Teriparatide as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (8 of 40 signal terms matched).

NCT01343004 — Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausa (N=2463, PHASE3; 195 AE terms posted; arms: Placebo; BA058 80 mcg (Abaloparatide); Teriparatide)
NCT01709110 — VERtebral Fracture Treatment Comparisons in Osteoporotic Women (N=1366, PHASE4; 226 AE terms posted; arms: Teriparatide; Risedronate)

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Nausea	9,008	2.1 2.1–2.2ROR 2.2 · calibrated p 0.927	2.1 EB05 2.1 · IC025 +1.1 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.2 · serious PRR 1.6 · 83% consumer	NCT01343004: 42/818 (5.1%) on Teriparatide; 25/820 (3.0%) control
Arthralgia (joint pain)	8,705	4.0 3.9–4.1ROR 4.2 · calibrated p 0.335	3.9 EB05 3.9 · IC025 +1.9 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.8 · serious PRR 2.4 · 85% consumer	NCT01343004: 1/818 (0.1%) on Teriparatide; 1/820 (0.1%) control (serious AE)
Pain in extremity	8,366	5.4 5.3–5.5ROR 5.8 · calibrated p 0.164	5.3 EB05 5.2 · IC025 +2.4 3/3 methods agree	Not in label — unassessed	age-adj. PRR 4.8 · serious PRR 3.3 · 87% consumer	NCT01343004: 42/818 (5.1%) on Teriparatide; 49/820 (6.0%) control
Dizziness	8,320	3.2 3.1–3.2ROR 3.3 · calibrated p 0.527	3.1 EB05 3.1 · IC025 +1.6 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.0 · serious PRR 2.3 · 82% consumer	NCT01343004: 2/818 (0.2%) on Teriparatide; 1/820 (0.1%) control (serious AE)
Fall	7,917	4.5 4.4–4.6ROR 4.8 · calibrated p 0.256	4.5 EB05 4.4 · IC025 +2.1 3/3 methods agree	Not in label — unassessed	age-adj. PRR 3.0 · serious PRR 5.6 · 73% consumer	NCT01709110: 15/683 (2.2%) on Teriparatide (serious AE)
Pain	7,563	2.3 2.3–2.4ROR 2.4 · calibrated p 0.852	2.3 EB05 2.3 · IC025 +1.2 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.7 · serious PRR 1.7 · 84% consumer	NCT01343004: 1/822 (0.1%) on Teriparatide; 3/820 (0.4%) control (serious AE)
Fatigue (tiredness)	7,209	1.7 1.7–1.8ROR 1.8 · calibrated p 0.826	1.7 EB05 1.7 · IC025 +0.8	Labeled (related wording) related wording	age-adj. PRR 1.6 · serious PRR 1.3 · 82% consumer	not reported in cached trials
Back pain	5,933	4.9 4.8–5.0ROR 5.1 · calibrated p 0.225	4.8 EB05 4.7 · IC025 +2.2 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 4.4 · serious PRR 4.2 · 84% consumer	NCT01343004: 1/818 (0.1%) on Teriparatide; 3/820 (0.4%) control (serious AE)
Muscle spasms	5,749	6.0 5.9–6.2ROR 6.3 · calibrated p 0.132	5.9 EB05 5.7 · IC025 +2.5 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 5.6 · serious PRR 3.7 · 87% consumer	not reported in cached trials
Malaise (feeling unwell)	5,685	2.4 2.4–2.5ROR 2.5 · calibrated p 0.807	2.4 EB05 2.4 · IC025 +1.2 3/3 methods agree	Not in label — unassessed	age-adj. PRR 2.2 · serious PRR 2.2 · 87% consumer	not reported in cached trials
Headache	5,508	1.7 1.6–1.7ROR 1.7 · calibrated p 0.760	1.6 EB05 1.6 · IC025 +0.7	Labeled adverse reaction exact term	age-adj. PRR 2.0 · serious PRR 1.4 · 81% consumer	NCT01343004: 1/822 (0.1%) on Teriparatide (serious AE)
Asthenia (weakness)	5,448	2.7 2.7–2.8ROR 2.8 · calibrated p 0.686	2.7 EB05 2.7 · IC025 +1.4 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 2.2 · serious PRR 2.2 · 81% consumer	NCT01709110: 1/683 (0.1%) on Teriparatide (serious AE)
Injection site erythema (redness where injected)	5,066	8.0 7.8–8.2ROR 8.3 · calibrated p 0.059	7.7 EB05 7.5 · IC025 +2.9 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 10.7 · serious PRR 7.5 · 89% consumer	not reported in cached trials
Injection site pain (pain where injected)	4,833	3.0 2.9–3.1ROR 3.1 · calibrated p 0.594	3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree	Labeled adverse reaction exact term	age-adj. PRR 3.6 · serious PRR 4.4 · 89% consumer	NCT01343004: 1/822 (0.1%) on Teriparatide; 3/820 (0.4%) control (serious AE)
Injection site bruising	4,780	12.0 11.7–12.4ROR 12.5 · calibrated p 0.014 ✓	11.3 EB05 11.1 · IC025 +3.5 3/3 methods agree	Labeled (related wording) related wording	age-adj. PRR 12.2 · serious PRR 10.7 · 94% consumer	not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Growing pains — n=72, PRR 69.6
Chest wall pain — n=73, PRR 51.0
Osteitis deformans — n=50, PRR 34.4
Buttock pain — n=35, PRR 31.8
Pain exacerbated — n=35, PRR 31.8
Bone fissure — n=46, PRR 23.1
Medial tibial stress syndrome — n=37, PRR 22.3
Fear of falling — n=70, PRR 17.8
Lower extremity mass — n=47, PRR 15.1
Difficulty in walking — n=261, PRR 15.1

✓ A hand-written Bradford Hill causality assessment exists for this drug: Teriparatide ↔ Hypercalcaemia.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Teriparatide?

In FDA FAERS, the most frequently co-reported reaction terms for Teriparatide are nausea, arthralgia, pain in extremity, dizziness, fall, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Teriparatide have an FDA boxed warning?

No. The FDA label retrieved for Teriparatide has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Teriparatide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID ab322675-4769-45b0-b146-14fbaa3135d0, effective 20250616; matched on openfda.generic_name.exact:"TERIPARATIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,222 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query TERIPARATIDE, results-bearing studies sorted by enrollment)

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.